Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)

Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated eight PAH participants transitioned...

Descripción completa

Detalles Bibliográficos
Autores principales: Calcaianu, George, Calcaianu, Mihaela, Canuet, Matthieu, Enache, Irina, Kessler, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467933/
https://www.ncbi.nlm.nih.gov/pubmed/28597752
http://dx.doi.org/10.1177/2045893217702401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467933/
https://www.ncbi.nlm.nih.gov/pubmed/28597752
http://dx.doi.org/10.1177/2045893217702401

Ejemplares similares